Pseudomonas aeruginosa

Phase II trial results presented at ATS 2025 demonstrate gremubamab's ability to significantly reduce Pseudomonas aeruginosa bacterial load in bronchiectasis patients, potentially offering an alternative to antibiotics.

Phase 3b trial demonstrates colonoscopic administration of Rebyota (fecal microbiota live-jslm) achieves 95.1% treatment success in preventing recurrent C. difficile infection with minimal adverse events.

Armata Pharmaceuticals' Phase 1b/2a diSArm trial demonstrated that AP-SA02, a novel intravenous bacteriophage therapy, met all primary endpoints for safety, tolerability, and clinical response in complicated Staphylococcus aureus bacteremia.

New data from the PROVE study reveals cefiderocol achieves better clinical outcomes when used as empiric (64.6%) or documented therapy (67.4%) compared to salvage therapy (58.2%) in serious gram-negative infections.

Owlstone Medical has secured a $2.3 million equity investment from the Cystic Fibrosis Foundation to develop a breath test for detecting Pseudomonas aeruginosa infections in CF patients.